Compare Plby Group Inc (PLBY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Zoetis Inc — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 255.5× Plby Group Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Zoetis Inc for 70 Days on average.
| PLBY | ZTS | |
|---|---|---|
Market Cap | $118.21M | $30.20B |
Volume | 919,783 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $147.53 |
52-Week Low | $0.99 | $69.09 |
Typical Hold Time | 24 Days | 70 Days |
Enterprise Value | $263.80M | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.97, down 4.5% today, with a bearish technical outlook despite analyst optimism. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses, though it remains unprofitable with negative equity. Recent leadership appointments signal strategic focus on brand growth and licensing expansion.
The stock presents a turnaround opportunity with strong analyst support (75% buy ratings) but carries significant risk from high debt levels and negative shareholder equity. Near-term catalysts depend on execution of the media and experiences strategy, while competitive pressures and cash flow volatility remain concerns.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
